Introduction
Colorectal cancer (CRC) is one of the leading causes of death worldwide in both men and women (1) . Antineoplastic drugs are widely used for CRC treatment but drug resistance and/or off-target toxicity limit their efficiency (2, 3) . Therefore, the development of novel anti-CRC agents is strikingly important.
The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates protein translation and controls key cellular processes such as cell metabolism, growth, proliferation, angiogenesis and survival, by integrating signals from growth factors, nutrients and energy status (4, 5) . It is known that mTOR, acting downstream of the phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/Akt signaling, forms two multiprotein complexes: mTORC1, sensitive to Rapamycin, and mTORC2, resistant to Rapamycin, which have distinct physiological functions. In particular, mTORC1 regulates messenger RNA (mRNA) expression, ribosome biogenesis, cellular growth, proliferation and survival (4, 6) . In response to mitogenic stimuli or nutrient availability, mTORC1 is activated, leading to phosphorylation of two well-characterized downstream effectors: the 70 kDa ribosomal protein S6 kinase (p70S6K) and the eukaryotic translation initiation factor 4E (eIF4E) binding protein 1 (4EBP1), which together control protein synthesis (7) .
mTOR is an oncogene that plays a pivotal role in several human cancers (8) (9) (10) . Emerging data have shown that components of the mTOR signaling pathway are frequently activated or overexpressed in CRC, representing a promising therapeutic target (5, 11, 12) .
Rapamycin and its analogs (rapalogs) like RAD001 (everolimus Novartis), AP23573 (Ariad Pharmaceuticals) and CCI779 (temsirolimus) are the most well-studied mTORC1 inhibitors. One problem regarding the use of this class of drugs for cancer treatment is related to a distinct spectrum of dose-limiting toxicities (13) such as skin reactions, mucositis and myelosuppression (11, 14) .
In nature, fruits and vegetables are an important source of phytochemicals which have chemopreventive activities; however, they can also be suitable for cancer treatment (15) . In particular, epigallocatechin-3-gallate (EGCG), the most important polyphenol from green tea, inhibits cell growth and proliferation in vitro, inducing apoptosis on CRC cells (16, 17) .
Another important source of phytochemicals, in particular proanthocyanidins, is grape seed (GS) extract. Data indicate that GS extract has strong growth inhibitory and apoptosis-inducing effects in CRC cell lines (18, 19) and xenografts (20) . Fish oil is a source of omega-3 (ω-3) polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA). EPA inhibits cell proliferation and tumor growth in murine and rodent models (21, 22) . Moreover, EPA has an effect in reducing the size of liver metastases in animal models (23) (24) (25) . Overall, literature data show that each of the three compounds mentioned above, tested as single molecules, have strong effects on CRC cells (26) (27) (28) , and EGCG and EPA have been found to act on the PI3K/Akt/mTOR pathway (29, 30) . However, to achieve anticancer effects, dosages are usually high. This would make natural compounds toxic rather than beneficial.
To minimize the toxic effects produced by the use of single agents at high concentrations and to develop a strategy more suitable in humans, in this study, we tested for the first time a combination of EPA as free fatty acid (FFA), EGCG and GS extract at low toxicity dosage, on mTOR signaling and on translational regulation in CRC cell lines. We found that this combination completely inhibited the mTOR signaling, led to changes of protein translation, reduced cell proliferation and induced apoptosis in CRC cells.
Materials and methods

Cell lines and treatments
The human CRC cell lines HCT116 (PIK3CA mutant, Rapamycin sensitive, p53 wild-type) and SW480 (PIK3CA wild-type, Rapamycin resistant, p53 mutant) were obtained from ATCC (Manassas, VA) and cultured in IMDM Abbreviations: CRC, colorectal cancer; EPA-FFA, eicosapentaenoic acidfree fatty acid; EGCG, epigallocatechin-3-gallate; GS, grape seed; mRNA, messenger RNA; mTOR, mammalian target of rapamycin.
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supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine (Euroclone, Milan, Italy). Cells were maintained at 37°C and 5% CO 2 . In our laboratory, all cells are tested and authenticated every year using known genetic and epigenetic markers.
Eicosapentaenoic acid-free fatty acid (EPA-FFA, ALFA, SLA Pharma AG, Switzerland), EGCG (purity ≥95%, Sigma-Aldrich, Milan, Italy), GS (purchased at a local market) extract and Rapamycin (Cell Signaling Technology, Milan, Italy) were used for cell culture treatments.
Preparation of GS extracts
One hundred grams of Aglianico red GSs were freeze dried and finely ground in a blender. They were then extracted three times with 200 ml of methanol obtaining the crude extract that was analyzed by liquid chromatography coupled with tandem mass spectrometry, as described previously (31) . The main compounds identified were catechins, dimers and trimers, although significant amounts of polymers, up to 8 units, were also detected. To obtain the molar concentration of GS extract, the sum of all peaks present in the chromatogram were considered and quantified using the calibration curve of procyanidin B2. Therefore, the GS amount was expressed in procyanidin B2 equivalents. In particular, GS extract 10 mmol/l procyanidin B2 equivalents were prepared and opportunely diluted for cell treatments.
Cell viability assay
Cells were seeded into 96-well plates (3 × 10 3 cells/well) and treated with different concentrations of EPA-FFA (0-300 µM), EGCG (0-400 µM) and GS (0-200 µM) in combination. After 24-96 h treatment, the number of viable cells compared with the control was measured using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay (MTT, Sigma-Aldrich) following the manufacturer's instructions. Each experiment was performed in quintuplicate and repeated independently twice.
Colony-forming assay
Cells were seeded in six-well plates (10 3 cells/well) and treated with a combination of EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM or Rapamycin 20 nM for 24 h. After colony formation, the plates were washed with phosphate-buffered saline and fixed with 0.5% crystal violet in paraformaldehyde. The total number of visible colonies was counted using ImageJ software (rsbweb.nih.gov/ij/). Each experiment was performed in triplicate and repeated independently three times.
Cell cycle analysis
Upon treatment with EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM or Rapamycin 20 nM for 24 h, cells were trypsinized, pelleted and resuspended in the Nusse 1 solution (NaCl 584 mg/l, trisodium citrate 1139 mg/l, ribonuclease 10 mg/l and Nonidet P40 300 µg/l) to obtain a final concentration of 2 × 10 6 cells/ml and incubated for 45 min on ice. An equal amount of Nusse 2 solution (sucrose 85.5 g/l and citric acid 15 g/l) was then added to the mixture to obtain a final concentration of 10 6 cells/ml. Samples were stained with propidium iodide (50 µg/ml) for 15 min and analyzed by flow cytometry (FACSAria, BD Biosciences, Milan, Italy).
Apoptosis analysis
Cells were treated for 24 h with the combination of EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM or Rapamycin 20 nM. Apoptosis was evaluated with the DeadEnd fluorometric TUNEL System (Promega, Milan, Italy), according to the manufacturer's recommendations. The apoptotic index was expressed as the number of apoptotic cells/total cells.
Western blot analysis
Cells were treated with EPA-FFA, EGCG and GS as single compounds or in combination or with Rapamycin 20 nM for 4-8 h. These time points were chosen because in the literature the effects on mTOR targets are studied between 1 and 8 h of treatment (32) . Fifty micrograms of proteins for each sample were separated on a 4-12% sodium dodecyl sulfate-polyacrylamide gel (Life Technologies, Monza, Italy) and transferred onto nitrocellulose membrane. After blocking, membranes were incubated overnight at 4°C with primary antibodies: phosphorylated p70S6K (Thr389) (1:1000), total p70S6K (1:800) and 4E-BP1 (1:600) (Cell Signaling Technology), phosphorylated 4E-BP1 (Ser65/Thr70) (1:1000), cyclin D1 (1:500) and c-Myc (1:500) (Santa Cruz Biotechnology, CA). After incubation with the secondary antibody, the signal was detected with a luminol enhancer solution (Chemiluminescent Sensitive Plus HRP, BioFx), and images were acquired with the Chemidoc TM XRS+ (Biorad). β-Actin (Sigma-Aldrich) was used as housekeeping protein. Each experiment was repeated three times.
Polysome analysis
Cells were treated with the combination of EPA-FFA 150 µM, EGCG 175µM and GS 15 µM or Rapamycin 20 nM for 4 h. Because mTOR regulates mRNAs actively translated, we chose to analyze the polysome profile at the same time as when we studied the effect of the combination, or of Rapamycin, on mTOR targets. Cells were then washed with phosphate-buffered saline containing 100 µg/ml cycloheximide (Sigma-Aldrich), pelleted at 1500 rpm for 5 min at 4°C and lysed in buffer containing 100 µg/ml cycloheximide and ribonuclease inhibitor 0.04 U/µl (Promega). Lysates were then centrifuged at 14 000 rpm for 10 min at 4°C. Supernatants were loaded onto 11 ml 15-50% sucrose gradient and centrifuged at 36 000 rpm for 2 h at 4°C. After centrifugation, gradients were fractionated manually (150 µl fractions) and the optical density of each fraction was measured with Nanodrop (Thermo Fischer Scientific, Illkirch Cedex, France).
RNA extraction and quantitative RT-PCR
Total and polysomal RNA were isolated using Trizol reagent according to the manufacturer's instructions and reverse transcribed using GoScript TM Reverse Transcriptase Kit (Promega, Milan, Italy). Quantitative RT-PCR (qRT-PCR) was performed using TaqMan Gene Expression Assays for c-Myc (Hs 00153408-m1) and cyclin D1 (Hs 00154737-m1) or Sybr Select Master mix for L5, L11, L13, β-actin (Life Technologies). Primer sequences for Sybr Green assays are reported in Supplementary Table I, available at Carcinogenesis Online. qRT-PCR was performed on iCycler (Bio-Rad) and data were analyzed with the 2 −ΔΔCt method using β-actin as housekeeping gene, except for mRNA associated with polysomes. For each sample, three replicates were analyzed.
Statistical analysis
Data were analyzed using Statistics 9.0 Software and Graphpad 5.0 Software (Graphpad Software, CA). When necessary, values were transformed using the function Y = log(Y) to stabilize variances. For continuous variables, the unpaired t-test and one sample t-test were used to evaluate the mean differences between two unmatched groups and a reference value, respectively. Oneway analysis of variance followed by Tukey's or Dunnett's post hoc tests were used for pairwise comparisons. Data are shown as means ± SEM. P values less than 0.05 were regarded as statistically significant.
Results
Treatment with EPA-FFA, EGCG and GS decreases mTOR activity in CRC cells
To investigate the effect of EPA-FFA, EGCG and GS on cell viability, we treated HCT116 and SW480 cells with different concentrations of the compounds in combination for 24 h. We found that the treatment with the combination of EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM (hereafter named as EPA-FFA+EGCG+GS) caused a decrease in the number of viable cells compared with the control in HCT116 (P < 0.01) and SW480 (P < 0.001) cells, respectively ( Figure 1A and B left) . In addition, we tested the effect of the combination of EPA-FFA+EGCG+GS in HCT116 and SW480 cells at 48, 72 and 96 h, finding a significant decrease at all the time points tested compared with the control (P < 0.001 for both HCT116 and SW480). Importantly, the inhibitory effect on cell viability persisted for 24 h in the absence of the combination (Supplementary Figure 1 , available at Carcinogenesis Online).
We then evaluated the phosphorylation status of two well-known mTOR downstream effectors, p70S6K and 4EBP1, in treated cells at 4 h (Figure 1 ) and 8 h (Supplementary Figure 2 , available at Carcinogenesis Online). As shown in Figure 1A (right), the treatment for 4 h on HCT116 cells with EPA-FFA and EGCG used as single compounds decreased the phosphorylation of p70S6K, whereas GS increased or did not change the levels of this protein. However, the phosphorylation of 4EBP1 did not seem to be significantly affected when all three natural substances were used as single compounds. Importantly, the treatment with the combination of EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM at 4 h significantly reduced the levels of P-p70S6K (P < 0.05) and p-4EBP1 (P < 0.05) compared with the control, achieving a stronger effect than the one obtained by using the mTOR inhibitor Rapamycin at 20 nM (P = n.s. control versus Rapamycin for both P-p70S6K and p-4EBP1). Because of these effects, we decided to perform all the experiments on p70S6K and 4EBP1 phosphorylation at 4 h.
We also tested the effect of the different combinations of EPA-FFA, EGCG and GS in SW480 cells at 4 h and we found that the combined treatment with EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM resulted in a significant reduction of P-4EBP1 (P < 0.001 control versus combination) comparable to Rapamycin (P < 0.01 control versus Rapamycin) and a decrease of P-p70S6K compared with control, even though this latter did not reach statistical significance ( Figure 1B  right) .
In addition, we tested whether the inhibitory effect of EPA-FFA+EGCG+GS at 4 h on mTOR targets persisted after the removal of the treatment. Both in HCT116 and SW480 cells, the modulation of p70S6K and 4EBP1 phosphorylation was lost 20 h after the removal of the combination (Supplementary Figure 3 , available at Carcinogenesis Online).
These results indicate that the combined treatment with EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM at low toxicity concentrations for 4 h inhibits mTOR signaling in HCT116 and SW480 cell lines, as shown by inhibition of its downstream effectors.
EPA-FFA, EGCG and GS treatment reduces translation of ribosomal proteins, c-Myc and cyclin D1 in CRC cells
Because mTOR regulates the initiation of translation, we next examined the effects of EPA-FFA+EGCG+GS for 4 h on translational regulation through the analysis of polysome profiles in HCT116 (Figure 2A ). The sum of absorbance at 260 nm of polysomal fractions was lower in the treated sample compared with the control, but this difference was not statistically significant. However, when we evaluated the levels of selected mRNAs known to be translationally regulated by mTOR, such as those encoding for ribosomal proteins (L5, L11, L13), c-Myc and cyclin D1, we found a significant decrease of L5 in total RNA (P = 0.03), L11 (P = 0.03) and cyclin D1 (P = 0.005) in RNA associated with polysomal fractions ( Figure 2B) (33, 34) . In addition, the same analysis was performed in HCT116 cells treated with Rapamycin 20 nM for 4 h. No statistically significant difference was observed between the polysomal profiles of control and Rapamycin-treated cells (Supplementary Figure 4A , available at Carcinogenesis Online). We then evaluated total and polysomal levels of selected mRNAs encoding for ribosomal proteins in Rapamycin-treated cells finding a significant decrease only for L13 in total RNA (P = 0.03 control versus Rapamycin, Supplementary Figure 4B , available at Carcinogenesis Online). To identify the mRNAs that were subjected to transcriptional and/or translational regulation after the treatment with EPA-FFA+EGCG+GS, the relative translatability of mRNA was determined by normalizing the change in abundance in polysomal RNA to the change in abundance in total RNA for each mRNA (Poly/Total) ( Table I) . As reported previously (35) , mRNAs with a Poly/Total ratio of 0.65 or lower were considered as translationally decreased whereas those mRNAs with a Poly/Total ratio equal or higher to 1.5 were considered translationally increased. Our data suggest that the treatment with EPA-FFA+EGCG+GS significantly decreased the total mRNA abundance of L5 and reduced the translation of L11, L13, c-Myc and cyclin D1.
We then investigated whether the observed translational decrease of c-Myc and cyclin D1 mRNA might affect their protein levels. Compared with the control, in treated HCT116 cells, we found suppression of c-Myc (P < 0.05) and a decrease of cyclin D1 that, however, did not reach statistical significance. Notably, the treatment with Rapamycin did not affect the level of c-Myc and cyclin D1 compared with the control (P = n.s.), ( Figure 3A ). In addition, we assessed the effect of EPA-FFA+EGCG+GS or Rapamycin on c-Myc and cyclin D1 proteins in SW480 cells, without finding any difference from the control (P = n.s.) ( Figure 3B ).
EPA-FFA, EGCG and GS treatment inhibits cell proliferation and increases apoptosis in CRC cells
To understand whether the reduction of c-Myc and cyclin D1 could cause alterations in cell proliferation, we examined the effect of EPA-FFA+EGCG+GS treatment for 24 h on the clonogenic capability of HCT116 and SW480 cells ( Figure 4A ). We found a significant reduction of the number of colonies in HCT116 and SW480 cells treated with the combination (P < 0.001 and P < 0.01, respectively). No significant reduction in the number of colonies was obtained by treating cells with Rapamycin 20 nM for 24 h. , GS (0-15 µM) and the number of viable cells compared with the control (%) was assessed with MTT assay (ANOVA P = 0.0016, **P < 0.01 Dunnett's test, n = 3) (left). mTOR downstream targets P-p70S6K, p70S6K, P-4EBP1, 4EBP1 were detected by western blotting on cells treated with compounds alone or in combinations or with Rapamycin. Statistical significance was tested only on HCT116 cells treated with EPA-FFA 150 µM, EGCG 175 µM, GS 15 µM or Rapamycin compared with the control (untreated cells) using one-way ANOVA (P = 0.0285 for P-p70S6K on logarithmic transformed data and P = 0.0347 for P-4EBP1) followed by Tukey's test, n = 4 (right). (B) SW480 cells were treated with EPA-FFA, EGCG and GS and the number of viable cells compared with the control was evaluated with MTT assay (ANOVA P = 0.0004, *P < 0.05; ***P < 0.001 Dunnett's test, n = 3) (left). mTOR downstream targets P-p70S6K, p70S6K, P-4EBP1, 4EBP1 were assessed upon treatment. Statistical significance was tested on SW480 cells treated with EPA-FFA 150 µM, EGCG 175 µM, GS 15 µM or Rapamycin 20 nM compared with the control (untreated cells) using one-way ANOVA (P = 0.0294 for P-p70S6K on logarithmic transformed data and P = 0.0008 for P-4EBP1) followed by Tukey's test, n = 4 (right).
In addition, we performed a cell cycle analysis in both cell lines after treatment with the combined EPA-FFA+EGCG+GS mixture or with Rapamycin 20 nM for 24 h. As shown in Figure 4B , in HCT116, the combined mixture significantly increased cells in the G 0 G 1 phase and reduced cells in the S and G 2 M phases (P < 0.01 control versus combination), whereas Rapamycin did not change the distribution of cells in the different cell cycle phases (P = n.s. control versus Rapamycin). Conversely, the treatment with either the combination or Rapamycin did not cause alteration of the cell cycle in SW480 cells (P = n.s.). We then evaluated whether treatment with EPA-FFA+EGCG+GS affects apoptosis, and we found a significant increase in the apoptotic index both in HCT116 (P < 0.05 control versus combination) ( Figure 4C ) and SW480 cells (P < 0.001 control versus combination). Furthermore, we assessed apoptosis on HCT116 and SW480 cells treated with Rapamycin, finding no differences compared with untreated control cells (P = n.s.).
Our data indicate that this low cytotoxic combination has antiproliferative and proapoptotic effects in CRC cell lines. In particular, EPA-FFA+EGCG+GS treatment was more effective than Rapamycin in the tested CRC cell lines and this is in line with the effects observed at the molecular levels described above.
Discussion
In this study, we have shown that the treatment with a combination of three natural compounds, EPA-FFA, EGCG and GS, at low cytotoxic concentrations, decreased mTOR activity in CRC cell lines leading to a reduced translation of the c-Myc and cyclin D1 cancer genes. These effects were stronger than those obtained with the selective mTOR inhibitor Rapamycin. In addition, the EPA-FFA, EGCG and GS treatment affected proliferation with a block of cells in G 0 G 1 phase and increased apoptosis.
The mTOR pathway is a central regulator of many cellular events, such as proliferation, growth, metabolism and survival and is frequently activated in CRC, due to a gain of function mutation of the PI3K catalytic subunit gene (36) (37) (38) . With its biological role and its constitutive activation in CRC, mTOR has become a key target of cancer research and drug development. Several studies have shown that pharmacological inhibitors of mTOR reduce the growth of CRC cells in vitro and in vivo, but clinical studies highlight drawbacks related to toxicity that could lead to treatment failure (11, 13, 14) . Moreover, mutations in the PI3K catalytic subunit that confer resistance to some inhibitors have been identified (39). Statistical significance was assessed using unpaired t-test (P = n.s., n = 2) (B) mRNA levels of L5, L11, L13, c-Myc and cyclin D1 were assessed by qRT-PCR both in total RNA and in polysomal associated RNA. Statistical significance was assessed using one sample t-test, n = 2, using 100 (control) as the reference value. 
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Phytochemicals have been widely used in chemoprevention. They could overcome off-target toxicity and drug resistance when used as anticancer agents and might represent a cheaper strategy compared with the development of synthetic drugs (40, 41) . However, to obtain antineoplastic effects, dosages are usually increased. A recent study showed that EGCG in combination with curcumin inhibits the PI3K/ mTOR pathway in leiomyosarcoma cells, although the concentrations used in that study were higher than ours (42, 43) . It had also been reported that EPA downregulates PI3K/mTOR signaling in CRC cells in combination with lycopene (30) . In the search for new approaches to minimize toxic effects due to the use of single agents at high concentrations, we tested for the first time a low cytotoxic combination of EPA-FFA 150 µM, EGCG 175 µM and GS 15 µM on mTOR pathway in CRC cells. Using a combination of natural agents at lower concentrations might be relevant for future clinical approaches. Interestingly, by combining three bioactive compounds, we found a complete abrogation of p70S6K and 4EBP1 phosphorylation in HCT116 cells at 4 h that we did not obtain using each agent individually. However, because EGCG and EPA-FFA had moderate effects on p70S6K and 4EBP1, whereas GS had more limited effects, our results suggest a synergic inhibition obtained with the combination. Importantly, the combined treatment for 4 h also reduced the phosphorylation of p70S6K and 4EBP1 in SW480 cells. These effects were stronger for HCT116, and comparable for SW480, with respect to those obtained with the pharmacological inhibition of mTOR by Rapamycin. Even though the effect of the combined treatment on mTOR targets at 4 h was lost after combination removal for 20 h, the decrease in the number of viable cells persisted even after media shift.
It is known that phosphorylated p70S6K further phosphorylates the 40S ribosomal protein S6, leading to enhancement of the translation of mRNAs encoding for ribosomal proteins and translation factors (44) . In this study we found a consistent reduction of phosphorylated p70S6K and 4EBP1 in association with a decrease of polysomal actively translated mRNA in HCT116 cells treated with EPA-FFA+EGCG+GS. Indeed, we observed an increase of free ribosomal subunits and a decrease of RNA in polysomal fractions in the treated sample. In particular, the treatment decreased the total amount of ribosomal protein L5 together with the translatability of L11 and L13. Moreover, phosphorylated 4EBP1 promotes dissociation of 4EBP1 from eIF4E, thereby increasing the translation of cyclin D1 and c-Myc mRNAs (4, 6) . According to this hypothesis, our results show a reduction in the translatability of cyclin D1 and c-Myc mRNA in association with a decrease in protein expression in HCT116-treated cells with respect to controls. These data suggest that EPA-FFA+EGCG+GS treatment has a bigger effect on translation than on transcription in the subset of genes analyzed. A previous study that evaluated the effect of EPA alone in an AOM rodent model suggested that fish oil mainly causes transcriptional alterations (45) . We can speculate that EPA-FFA used alone act mainly on transcriptional regulation, whereas in combination with EGCG and GS they could cause translational alterations.
Furthermore, the decrease in cyclin D1 and c-Myc induces a significant reduction of clonogenic potential with a block of HCT116 cells in G 0 G 1 phase and induction of apoptosis in treated cells. In addition, a reduction of c-Myc and cyclin D1 proteins was observed in SW480-treated cells with a concomitant decrease of clonogenic potential. However, SW480 did not undergo a block of cell cycle in G 0 G 1 phase. This lack of block could be due to the mutation of the cell cycle regulator p53 in SW480 (20) . Moreover, the treatment with Rapamycin had no effect on c-Myc, cyclin D1, clonogenic potential, cell cycle and apoptosis. The failure of Rapamycin to inhibit cell proliferation could be due to the administration as a single agent at a low concentration as previously reported (46) . Overall, our findings suggest that in CRC the combination of EPA-FFA, EGCG and GS could be used at a concentration with lower toxicity than mTOR inhibitors. Because of the central role of mTOR signaling in CRC, the combined treatment with EPA-FFA, EGCG and GS may be considered a promising anti-CRC therapy and further investigations are thus warranted.
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